"Talk to anyone living with a chronic disease like diabetes and they will mention the struggle of having to inject themselvesin some caseseven multiple times a day," Exolvo Biosciences CEO Brian Longstreet says in a press release.
"There is a need for innovative solutions that can make treatments more accessible and less invasive for people that live with chronic conditions."
That's why the Dutch biotech company has just received $30 million in funding from NLC Health Ventures, the world's largest health-tech venture investor, reports the Wall Street Journal.
Exolvo's technology is designed to deliver biologic drugs, which are sensitive to digestive enzymes and the acidic environment of the gastrointestinal tract, per the press release.
Due to their size and complexity, biologics are sensitive to the digestive enzymes and acidic environment of the gastrointestinal tract, making oral delivery challenging.
As a result, biologic drugs are usually administered through frequent and painful needle injections or intravenous administration.
Exolvo's oral drug delivery technology is distinguished by its flexible capsule size and modular design, allowing adaptation to a variety of large molecular structures.
"This technology has tremendous potential for significant impact," says Nick Ibery, UK lead partner at NLC.
"For patients, it means an improved and
A customized collection of grant news from foundations and the federal government from around the Web.
Government efforts to promote entrepreneurship always fail because they focus on building science parks and top-down clusters.